Join
Live feed
·
PRReleasevia Quantisnow
CervoMed Inc. logo

CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

ByQuantisnow·Wall Street's wire, on your screen.
CRVO· CervoMed Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CRVO (CervoMed Inc.) and more on Quantisnow.